XM, Amerika Birleşik Devletleri'nde ikamet edenlere hizmet sunmamaktadır.

XM, Amerika Birleşik Devletleri'nde ikamet edenlere hizmet sunmamaktadır.
B
B

Biomarin

Haberler

Reuters - 7 saat önce

U.S. Aerovironment, Insulet, Viasat

U.S. RESEARCH ROUNDUP- Aerovironment, Insulet, Viasat Sept 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Aerovironment, Insulet and Viasat, on Tuesday. HIGHLIGHTS * Aerovironment Inc AVAV.O : Raymond James cuts to market perform from outperform * Frontier Communications Parent Inc FYBR.O : JP Morgan cuts to neutral from overweight * Insulet Corp PODD.O : Piper Sandler raises target price to $285 from $230 * Relm
B
C
C
E
I
D
Reuters - 21 saat önce

Ascendis rises on positive trial data for dwarfism therapy

BUZZ-Ascendis rises on positive trial data for dwarfism therapy ** U.S.-listed shares of Denmark-based Ascendis Pharma A71.F , ASND.O rise 17.3% to $139.88 ** ASND says its achondroplasia therapy TransCon CNP met its main goal by showing an average growth velocity of 5.89 cm/year vs 4.41 cm/year for a placebo in a trial ** Achondroplasia is a form
B
Reuters - 2 hafta önce

U.S. Coca-Cola, KB Home, Newmark Group

U.S. RESEARCH ROUNDUP-Coca-Cola, KB Home, Newmark Group Sept 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Coca-Cola, KB Home and Newmark Group on Thursday. HIGHLIGHTS * Capital Clean Energy Carriers CCEC.O : Evercore ISI initiates coverage with outperform rating * Coca-Cola Co KO.N : CFRA cuts to hold from buy * KB Home KBH.N : RBC cuts to underperform from sector perform * Newmark Group Inc NMRK.O : KBW raises
B
U
C
D
C
C
L
Reuters - 2 hafta önce

Biomarin Pharmaceutical Says On Aug 28, Entered Into Credit Agreement For Up To $600 Million In Revolving Loans

BRIEF-Biomarin Pharmaceutical Says On Aug 28, Entered Into Credit Agreement For Up To $600 Million In Revolving Loans Sept 4 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O : BIOMARIN PHARMACEUTICAL: ON AUG 28, ENTERED INTO CREDIT AGREEMENT FOR UP TO $600 MILLION IN REVOLVING LOANS BIOMARIN PHARMACEUTICAL: CO WILL BE ENTITLED TO DRAW FUNDS AT ITS DI
B
Reuters - 2 hafta önce

Biomarin Holds Investor Day; Provides New Corporate Strategy And Introduces 2027 Financial Guidance

BRIEF-Biomarin Holds Investor Day; Provides New Corporate Strategy And Introduces 2027 Financial Guidance Sept 4 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O : BIOMARIN HOLDS INVESTOR DAY; PROVIDES NEW CORPORATE STRATEGY AND INTRODUCES 2027 FINANCIAL GUIDANCE BIOMARIN PHARMACEUTICAL: SEES FY 2027 TOTAL REVENUES $4 BILLION BIOMARIN PHARMACEUTICAL:
B
Reuters - 3 hafta önce

BioMarin to reduce global workforce by about 225 employees

UPDATE 2-BioMarin to reduce global workforce by about 225 employees Adds job reduction details in paragraphs 4-6 Aug 28 (Reuters) - BioMarin Pharmaceutical BMRN.O w ill reduce its global workforce by about 225 employees, a filing showed on Wednesday. The decision comes in the wake of the company's updated strategy for its hemophilia gene therapy, Roctavian, and the discontinuation of its gene therapy BMN 293 development program.
B
Reuters - 3 hafta önce

BioMarin to reduce global workforce by about 225 employees

BioMarin to reduce global workforce by about 225 employees Aug 28 (Reuters) - BioMarin Pharmaceutical BMRN.O has decided to reduce its global workforce by about 225 employees, a filing showed on Wednesday. Reporting by Sriparna Roy in Bengaluru; Editing by Maju Samuel
B
Reuters - 4 hafta önce

U.S. Agree Realty, Global Payments, Snowflake

U.S. RESEARCH ROUNDUP- Agree Realty, Global Payments, Snowflake Aug 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Agree Realty, Global Payments and Snowflake on Wednesday. HIGHLIGHTS * Agree Realty Corp ADC.N : Raymond James raises target price to $81 from $70 * Coinbase Global Inc COIN.O : Jefferies cuts target price to $220 from $245 * Global Payments Inc GPN.N : Jefferies raises target price to $130 from $120
A
B
C
C
P
V
E
G
M
K
L
Reuters - 4 hafta önce

U.S. Alight, Mastercard, Visa

U.S. RESEARCH ROUNDUP-Alight, Mastercard, Visa Aug 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alight, Mastercard and Visa, on Tuesday. HIGHLIGHTS * Alight Inc ALIT.N : JP Morgan cuts to neutral from overweight * Biomarin Pharmaceutical Inc BMRN.O : Bernstein raises to outperform from market-perform * Liquidia Corp LQDA.O : Raymond James raises to strong buy from outperform * Mastercard MA.N : JP Morgan raises
A
A
B
D
P
P
V
A
D
T
A
E
F
G
Z
B
D
Reuters - 1 ay önce

U.S. STOCKS IDEXX, Amgen, Airbnb

BUZZ-U.S. STOCKS ON THE MOVE-IDEXX, Amgen, Airbnb Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes rose over 1% on Tuesday, as investors looked for bargains after a global stock selloff and dovish comments from Federal Reserve officials lifted market sentiment.
A
A
B
I
U
U
F
M
R
U
V
M
Reuters - 1 ay önce

U.S. STOCKS Lumen Technologies, Broadridge Financial, IDEXX

BUZZ-U.S. STOCKS ON THE MOVE-Lumen Technologies, Broadridge Financial, IDEXX Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes rose over 1% on Tuesday, as investors looked for bargains after a global stock selloff and dovish comments from Federal Reserve officials lifted market sentiment.
A
A
B
C
I
U
U
F
M
R
T
U
B
J
M
Reuters - 1 ay önce

BioMarin up as investors applaud new focus for hemophilia gene therapy

BUZZ-BioMarin up as investors applaud new focus for hemophilia gene therapy ** Shares of BioMarin Pharmaceutical BMRN.O rise ~8% to hit over 3-month high of $86.48 ** BMRN plans to cut direct annual expenses for its hemophilia gene therapy, Roctavian , by directing commercial focus to markets in the U.S., Germany and Italy ** Co anticipates reducing annual direct expenses on Roctavian to ~$60 million beginning in 2025 ** "Investors appear to be applauding the decision to downsize Roctavian's exp
B
Reuters - 1 ay önce

Leerink views Lilly and Sarepta as defensive stocks in turbulent market

BUZZ-Leerink views Lilly and Sarepta as defensive stocks in turbulent market ** Brokerages Leerink Partners says Eli Lilly LLY.N and Sarepta Therapeutics SRPT.O are among stocks it expects to outperform the broader market in "this turbulent period" of recession concerns ** Brokerage expects strong performance from the weight-loss and diabetes drug maker LLY on Wed, when it reports its earnings ** SRPT is a "a potential haven for investors seeking downside protection in a choppy market" due to po
A
B
M
T
Reuters - 1 ay önce

U.S. Actinium, Albemarle, ArcBest

U.S. RESEARCH ROUNDUP- Actinium, Albemarle, ArcBest Aug 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Actinium Pharmaceuticals, Albemarle and ArcBest, on Tuesday. HIGHLIGHTS * Actinium Pharmaceuticals Inc ATNM.A : JonesTrading cuts PT to $9 from $26 * Albemarle ALB.N : Baird cuts to neutral; cuts target price to $85 from $102 * ArcBest Corp ARCB.O : Stephens cuts target price to $130 from $145 * Crispr Therapeuti
A
A
B
B
C
C
C
C
D
Reuters - 1 ay önce

Biomarin Pharmaceutical Inc reports results for the quarter ended in June - Earnings Summary

Biomarin Pharmaceutical Inc reports results for the quarter ended in June - Earnings Summary Biomarin Pharmaceutical Inc BMRN.OQ reported quarterly adjusted earnings of 56 cents​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of 29 cents. The mean expectation of twenty five analysts for the quarter was for earnings of 35 cents per share.
B
Reuters - 1 ay önce

BioMarin climbs after Q2 results beat

BUZZ-BioMarin climbs after Q2 results beat ** Shares of therapy developer BioMarin BMRN.O rise ~5.6% to $84.99 in after-hours trading ** BMRN reports Q2 adj. profit of 96 cents/shr vs analysts' average estimate of 35 cents/shr - LSEG data ** Company's quarterly revenue of $712 mln also beats analysts' expectation of $662.1 mln ** BMRN forecasts annual adj.
B
Reuters - 1 ay önce

Biomarin Pharmaceutical Q2 EPS USD 0.55

BRIEF-Biomarin Pharmaceutical Q2 EPS USD 0.55 Aug 05 (Reuters) - Biomarin Pharmaceutical Q2 revenue USD 712 million vs. IBES estimate USD 662.1 million. Q2 basic EPS USD 0.56 Q2 adjusted EPS USD 0.96 vs. IBES estimate USD 0.35 Q2 net income USD 107.2 million vs. IBES estimate USD 70.5 million
B
Reuters - 2 ay önce

US FDA Approves Biomarin's Brineura For Children Under 3 Years With CLN2 Disease

BRIEF-US FDA Approves Biomarin's Brineura For Children Under 3 Years With CLN2 Disease July 24 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O : U.S. FOOD AND DRUG ADMINISTRATION APPROVES BIOMARIN'S BRINEURA® (CERLIPONASE ALFA) FOR CHILDREN UNDER 3 YEARS WITH CLN2 DISEASE Source text for Eikon: ID:nPn4g5vV5a Further company coverage: BMRN.O
B
Reuters - 2 ay önce

Pfizer's gene therapy cuts hemophilia A bleeding rate in late-stage trial

UPDATE 1-Pfizer's gene therapy cuts hemophilia A bleeding rate in late-stage trial Adds background on data and disorder throughout July 24 (Reuters) - Pfizer's PFE.N gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study and performed better than the current standard treatment, the company said on Wednesday.
B
P

Şartlar

Popüler varlıklar

Bildirim: XM Group şirketlerinin her biri yalnızca gerçekleştirme hizmeti ve online yatırım platformumuza erişim sağlar. Herhangi bir kişinin web sitesinde bulunan veya web sitesi üzerinden sağlanan içeriği görüntülemesine ve/veya kullanmasına izin vermek, bu hizmeti değiştirmek veya genişletmek amaçlı değildir ve bu hizmeti ne değiştirir ne de genişletir. Bu tür erişim ve kullanım her zaman şunlara tabidir: (i) Şartlar ve Koşullar; (ii) Risk Uyarıları ve (iii) Tam Bildirim. Bu nedenle bu tür içerikler yalnızca genel bilgi amacıyla sağlanır. Özellikle, online yatırım platformumuzun içeriklerinin finans piyasalarında herhangi bir işleme girmek için bir teşvik veya bir teklif olmadığını lütfen dikkate alın. Herhangi bir finans piyasasında yatırım yapmak sermayeniz için önemli düzeyde risk taşır.

Online yatırım platformumuzda yayınlanan tüm materyaller yalnızca eğitim/bilgilendirme amaçlıdır ve finansal tavsiye, yatırım vergisi veya yatırım tavsiyesi ve önerileri ya da yatırım fiyatlarımızın kaydı veya herhangi bir finansal enstrümanda işlem yapılması için bir teklif veya teşvik ya da talep edilmemiş finansal promosyonları içermez ve içerdiği şeklinde bir değerlendirme yapılmamalıdır.

Görüşler, haberler, araştırma, analizler, fiyatlar, diğer bilgiler veya bu web sitesinde bulunan üçüncü taraf sitelere verilen bağlantılar gibi her türlü üçüncü taraf içeriğin yanı sıra XM tarafından hazırlanan içerik de “olduğu gibi” esasına göre, genel piyasa yorumu olarak sağlanır ve bir yatırım tavsiyesi oluşturmaz. Herhangi bir içeriğin yatırım araştırması olarak yorumlanmasıyla ilgili olarak, içeriğin bağımsız yatırım araştırmasını desteklemek üzere tasarlanmış yasal gerekliliklere uygun hazırlanmadığını ve bu amacın güdülmediğini, aynı şekilde ilgili yasalar ve mevzuatlar kapsamında pazarlama iletişimi olarak değerlendirileceğini dikkate almalı ve kabul etmelisiniz. Buradan erişebileceğiniz Bağımsız Olmayan Yatırım Araştırması Bildirimimizi ve yukarıdaki bilgilerle ilgili Risk Uyarımızı okuduğunuzdan ve anladığınızdan emin olun.

Risk uyarısı: Sermayeniz risk altında. Kaldıraçlı ürünler herkese uygun olmayabilir. Lütfen Risk Bildirimi'mizi dikkate alın.